(Q44455773)

3 December 2017

title

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers (English)

1 reference

3 December 2017

6

1 reference

3 December 2017

P A Smink

1

1 reference

3 December 2017

J Hoekman

2

1 reference

3 December 2017

D E Grobbee

3

1 reference

3 December 2017

M J C Eijkemans

4

1 reference

3 December 2017

H-H Parving

5

1 reference

3 December 2017

H Ibsen

7

1 reference

3 December 2017

L Lindholm

8

1 reference

3 December 2017

K Wachtell

9

1 reference

3 December 2017

D de Zeeuw

10

1 reference

3 December 2017

H J Lambers Heerspink

11

1 reference

3 December 2017

publication date

6 March 2013

1 reference

European Journal of Preventive Cardiology

3 December 2017

published in

1 reference

3 December 2017

volume

21

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

434-441

1 reference

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2047487313481754

21 January 2018

Identifiers

DOI

10.1177/2047487313481754

1 reference

3 December 2017

1 reference